Presentation is loading. Please wait.

Presentation is loading. Please wait.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Published byEmma May Modified over 6 years ago

Similar presentations

Presentation on theme: "EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin."— Presentation transcript:

1 EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients 
Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin Chan, PhD, James Chung-Man Ho, MD, Mary Ip, MD, Wah-Kit Lam, MD, Tai-Kwong Chan, MD, Vivian Chan, PhD  Journal of Thoracic Oncology  Volume 7, Issue 7, Pages (July 2012) DOI: /JTO.0b013e Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A, Sensitivity experiment showing the detection of A-PCR products of exon 21 of the EGFR gene prepared from (A) equal amounts (100,000 copies) of cloned L858R mutant (mt) and wild-type (wt, from 300 ng normal genomic DNA), (B) 5000 copies L858R mt in the presence of wt, (C) 62.5 copies L858R mt in the presence of wt, and (D) 31 copies L858R mt in the presence of wt. Each panel shows a section of the array where oligonucleotide primers for detecting mutations in Exon 20 and Exon 21 of the EGFR gene are spotted. Primers are spotted twice, in triplicate rows. Wt = primers for wild type sequence and mt = primer for mutant sequence. The codon position of these sequences along the gene is indicated at the top of each panel. Note that fluorescent signal intensity is white > red > yellow > green, with blue as background. B, Sensitivity experiment showing the detection of A-PCR products of exon 18 of the EGFR gene prepared from (A) equal amounts (10,000) copies of cloned E709K + G719A mt and wt (from 30 ng normal genomic DNA), (B) 31 copies of the same Exon 18 mt and 10,000 copies wt, (C) equal amounts (10,000 copies) of cloned Exon 19 del mt and wt (30 ng genomic DNA), and (D) 125 copies Exon 19 mt in the presence of 10,000 copies wt. A-PCR, asymmetric PCR; EGFR, epidermal growth factor receptor; mt, mutant; wt, wild type. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Results of plasma-DNA analysis in a patient with NSCLC (TKL001), during 40 months’ longitudinal follow-up. Primers for detecting drug-resistant mutations are located at the right of each panel. NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin."

Similar presentations

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA  Tomomi Nakamura, MD, Naoko.

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA  Tomomi Nakamura, MD, Naoko.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene
Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-

Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Detection of Exon 12 Mutations in the JAK2 Gene

Detection of Exon 12 Mutations in the JAK2 Gene
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R
An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients  Antonio Marchetti, MD, PhD,

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients  Antonio Marchetti, MD, PhD,
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients  Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients  Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Similar presentations

Ads by Google